MTOR and breast carcinoma: Furthermore, activation of the phosphatidylinositol-3-kinase (PI3K)/AKT/mechanistic target of rapamycin (mTOR) pathway in ERα-positive breast cancers has been associated with relapse and death in patients treated with tamoxifen, supporting in vitro evidence that AKT mediates tamoxifen resistance [15].